Extends ban on drug manufacturer interference with 340B program

File HF2703 ("Extends ban on drug manufacturer interference with 340B program") is before the Minnesota Legislature and has not been decided. Latest step (April 13, 2026): Author changed.

Minnesota file HF2703, before the Minnesota Legislature. Still to be decided as of 2026-04-13.

What it does

Safety-net providers keep access to discounted drugs for uninsured patients. Hospitals and clinics serving uninsured and Medicaid patients retain access to the 340B drug discount program, which requires manufacturers to offer steep discounts on outpatient medications—preventing manufacturers from blocking or restricting this access through contractual workarounds.

The bigger picture

Protects funding model for rural and underserved hospital programs. The 340B savings enable safety-net hospitals to reinvest pharmacy margins into community health services, mental-health programs, and charity care—so extension of the manufacturer ban sustains the economic foundation of these institutions' community mission.

What to watch

Drug manufacturers may pursue legal or legislative challenges to the rule. Pharmaceutical makers have opposed 340B restrictions as reducing profit margins and innovation incentives, and the extension may face future legal attack or federal legislative rollback depending on administration priorities.

Official summary

Prohibition extended on manufacturers interfering with access to 340B drugs.

Read the official record for HF2703

See everything up for a vote · This week in Minnesota · See what we have filed with the clerk